JSJanice M. Staber

Janice M. Staber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Janice M. Staber has a total of 197 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost comparison of efanesoctocog alfa vs conventional factor VIII therapies for major surgeries in patients with severe hemophilia A

    by Janice M. Staber, Alix Arnaud, Ion Agirrezabal, Duygu Bozkaya, Lane Anson, Andrew Wilson, Nana Kragh, Doris Quon, Allison P. Wheeler

  • Open Access

    A New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the PREDICT Study

    by Doris V. Quon, Miguel Escobar, Lisa Boggio, Fernando F. Corrales-Medina, Akshat Jain, Mark T. Reding, Robert F. Sidonio, Janice M. Staber, Jessica Charlet

    Introduction There is currently no consensus on optimal prophylaxis with clotting factor concentrates in hemophilia A. With or without pharmacokinetic data, prophylaxis regimens are often based on local practice and patient-specific factors, including bleeding history and activity level. The PREDICT study evaluated a baseline clinical risk score, based on phenotypic and biologic variables, to guide prophylactic regimen selection when switching from standard half-life (SHL) factor VIII concentrates to damoctocog alfa pegol. Methods This multicenter, prospective study enrolled 21 participants aged ≥ 12 years with congenital hemophilia A of any severity who had received SHL prophylaxis for ≥ 6 months. Each participant was assigned a risk score (low, medium, high) based on five predefined variables: bleeding phenotype, treatment frequency, active target joints, von Willebrand factor levels, and physical activity. All participants initiated damoctocog alfa pegol at twice-weekly dosing for 4 weeks, after which regimens were individualized: 2×/week for high risk, every 5 days (Q5D) for medium risk, and Q5D for 4 weeks followed by less frequent dosing for low risk participants. A favorable outcome was defined as a reduction in annualized bleeding rate (ABR) and/or infusion frequency compared with previous SHL prophylaxis. Results Among 17 evaluable participants, 12 (70.6%) achieved a favorable outcome for treated and untreated bleeds. All 12 had improved ABR, and 11 required fewer infusions. When considering only treated bleeds, 77% achieved a favorable outcome. Mean ABR decreased by 8.01 and infusion frequency reduced by a mean of 6.9 infusions/month. The 25 active target joints identified at baseline were reduced by 96% at study completion. Conclusions The PREDICT risk-based scoring system-guided individualized prophylaxis with damoctocog alfa pegol, yielding improved bleeding outcomes and reduced treatment burden in most participants. These findings support the use of structured, risk-adapted approaches to personalize prophylaxis when transitioning from SHL to damoctocog alfa pegol. Trial Registration NCT05036278.

  • Platelet defects in patients and mice with Ehlers-Danlos syndrome

    by Mariia Kumskova, Gagan D. Flora, Manasa K. Nayak, Ivan Budnik, Aditi Jain, Rakesh B. Patel, Abhishek B. Jha, Madankumar Ghatge, Neelam Chauhan, James V. Michael, et al.

    Ehlers-Danlos syndrome (EDS) is a group of connective tissue disorders characterized by joint hypermobility, skin hyperelasticity, perivascular tissue fragility, easy bruising, and increased bleeding risk. Abnormal bleeding in EDS ranges from mild ecchymoses to life-threatening hemorrhage. Platelet function abnormalities have been reported in people with EDS, but the broad nature and extent of these defects remain poorly defined. Herein, we evaluated blood samples from people with the hypermobile, classical, classical-like, and vascular types of EDS, and used a Col5a1+/− mouse model of classical EDS to characterize the extent of platelet dysfunction. Our findings suggest that platelet dysfunction in EDS is an outcome of reduced integrin αIIbβ3 activation resulting from decreased phosphorylation of talin-1, leading to defects in aggregation and spreading. The observed platelet dysfunction was associated with reduced expression of the platelet surface receptors glycoprotein VI (GPVI) and proteinase-activated receptor 1 (PAR1) and impaired downstream signaling. Col5a1+/− mice demonstrated increased tail bleeding time, reproduced the signaling defects observed in platelets from people with EDS, and exhibited decreased susceptibility to FeCl3-induced carotid artery thrombosis. Collectively, our data indicate that platelet dysfunction in EDS is likely contributing to hemorrhagic complications.


  • Open Access

    Individual Comparative PK Evaluation of Single-dose Octocog Alfa, Rurioctocog Alfa Pegol, and Efanesoctocog Alfa in Adults with Severe Hemophilia A

    by Janice M. Staber, Toshko Lissitchkov, Anthony K. C. Chan, Andrew S. Wilson, Jennifer Dumont, Annemieke J. Willemze

  • Heavy menstrual bleeding clinics for adolescents

    by Maureen Baldwin, Kristina M. Haley, Janice M. Staber

    Heavy menstrual bleeding (HMB) is a common symptom in adolescence, often leading to significant disruptions in daily life, such as school absences, shame caused by the stigma surrounding menstruation, and symptoms from iron deficiency. Further, HMB may be the first and/or only sign of an underlying bleeding disorder. Navigating the symptoms, effects, and treatments of HMB during adolescence requires a collaborative approach between the patient, caregivers, and healthcare providers. This work can be effectively and efficiently conducted in interdisciplinary clinics, where patients see hematology, gynecology, and adolescent providers. In these settings, healthcare providers exchange knowledge and expertise, after which they can reach a consensus for diagnostic evaluation and therapeutic intervention. Development and implementation of an interdisciplinary hematology and gynecology clinic can be challenging; however, the crucial rationale is that established clinics improve patient outcomes. Using an example interdisciplinary adolescent clinic, we outline the critical components needed to execute a successful clinic for adolescents with HMB and share key takeaways.


  • Open Access

    Regional brain volumes and their relationship to neurocognitive outcomes in children with severe hemophilia A

    by Silvia Verhofste, Ahmad Al-Huniti, Marci Novak, Amy L. Conrad, Ellen van der Plas, Lyndsay Harshman, Janice M. Staber


  • Trends in dedicated care for females with bleeding disorders within U.S. hemophilia treatment centers

    by Allison P. Wheeler, Ming Y. Lim, Patricia S. Huguelet, Julie Jaffray, Janice M. Staber, Kerry Funkhouser, Shannon L. Carpenter, Angela C. Weyand

    Graphical representation of increasing percentage of female patients seen at HTCs, percentage of females by diagnosis, number of clinics in existence, and absolute number of female patients seen over a 10-year period (top left then clockwise). image


  • Characterization of bleeding symptoms in Ehlers–Danlos syndrome

    by Mariia Kumskova, Gagan D. Flora, Janice Staber, Steven R. Lentz, Anil K. Chauhan


  • Open Access

    The intersection of vector biology, gene therapy, and hemophilia

    by Leszek Lisowski, Janice M. Staber, J. Fraser Wright, Leonard A. Valentino


  • Open Access

    The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development

    by B. M. Reipert, B. Gangadharan, C. J. Hofbauer, V. Berg, H. Schweiger, J. Bowen, J. Blatny, K. Fijnvandraat, E. S. Mullins, J. Klintman, et al.

    Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need. Better understanding of the early events of evolving FVIII inhibitors is essential for risk identification and the design of novel strategies to prevent inhibitor development. The Hemophilia Inhibitor Previously Untreated Patients (PUPs) Study (HIPS; www.clinicaltrials.gov #NCT01652027) is the first prospective cohort study to evaluate comprehensive changes in the immune system during the first 50 exposure days (EDs) to FVIII in patients with severe hemophilia A. HIPS participants were enrolled prior to their first exposure to FVIII or blood products (“true PUPs”) and were evaluated for different immunological and clinical parameters at specified time points during their first 50 EDs to a single source of recombinant FVIII. Longitudinal antibody data resulting from this study indicate that there are 4 subgroups of patients expressing distinct signatures of FVIII-binding antibodies. Subgroup 1 did not develop any detectable FVIII-binding immunoglobulin G (IgG) antibodies. Subgroup 2 developed nonneutralizing, FVIII-binding IgG1 antibodies, but other FVIII-binding IgG subclasses were not observed. Subgroup 3 developed transient FVIII inhibitors associated with FVIII-binding IgG1 antibodies, similar to subgroup 2. Subgroup 4 developed persistent FVIII inhibitors associated with an initial development of high-affinity, FVIII-binding IgG1 antibodies, followed by IgG3 and IgG4 antibodies. Appearance of FVIII-binding IgG3 was always associated with persistent FVIII inhibitors and the subsequent development of FVIII-binding IgG4. Some of the antibody signatures identified in HIPS could serve as candidates for early biomarkers of FVIII inhibitor development.